Field report NW-14 / Q7 · sheet /deals
M&A & DealsFiled from the territory
J&J Pays $2.2 Billion Upfront for Eye Disease Biotech Ollin
J&J will pay $2.2 billion upfront for Ollin Biosciences, adding bispecific antibody OLN324 for wet AMD and diabetic macular edema. Blackstone funds the $750 million Phase 3 program.
- Grid
- NW-14 / Q7
- Surveyed
- November 20, 2026
- Reading
- 2 min read
- Correspondent
- Olivia Hart
Field notes
- J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, announced Monday.
- Blackstone Life Sciences will provide $750 million to fully fund Phase 3 development of OLN324.
- Milestone payments could add up to $1.125 billion if regulatory and commercial targets are met.
- OLN324 targets wet AMD and diabetic macular edema, affecting over 40 million people worldwide.
- The deal is expected to close before the end of 2026, following J&J's $1 billion Firefly Bio acquisition in June.
Johnson & Johnson has agreed to acquire Ollin Biosciences, a clinical-stage biotech focused on serious eye diseases, for $2.2 billion upfront. The deal, announced Monday, adds the investigational bispecific antibody OLN324 to J&J's pipeline and could carry up to $1.125 billion in additional payments tied to regulatory and commercial milestones.
For deal watchers, the structure matters as much as the price. Blackstone Life Sciences will separately pay J&J $750 million to fully fund Phase 3 development of OLN324, in exchange for single-digit royalties and milestone payments. J&J expects the transaction to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
What does OLN324 actually target?
The candidate hits two pathways in retinal disease at once: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). J&J is developing it for wet age-related macular degeneration and diabetic macular edema, conditions the company said affect more than 40 million people worldwide and rank among the leading causes of vision loss.
Kip Connor, vice president and ophthalmology disease area stronghold leader at J&J, said in a statement that OLN324 could reduce retinal fluid more effectively and allow more time between treatments. He said the data generated to date point to that potential.
That durability claim is the commercial hinge. Current anti-VEGF regimens require frequent injections, and a longer-acting dual-pathway agent would shift both patient compliance and pricing power in one of ophthalmology's largest markets.
How does the Blackstone funding work?
The financing is a separate development funding agreement, contingent on the acquisition closing. Blackstone will provide J&J a total of $750 million, spread across several years, to cover the entire cost of Phase 3 development of OLN324. In return, Blackstone could receive:
- Royalties in the single digits on the drug
- Certain payments tied to regulatory goals
- Certain payments tied to sales goals
J&J said it will communicate the accounting treatment on or before the close of the transaction.
The structure effectively de-risks the most expensive stage of clinical development without diluting J&J's ownership of the asset. For practitioners tracking pharma deal design, it extends the risk-sharing model that private capital players like Blackstone Life Sciences have pushed into late-stage pipelines.
Where does this fit in J&J's deal calendar?
The Ollin acquisition follows J&J's June agreement to buy Firefly Bio for $1 billion in cash. That transaction is also expected to close before the end of 2026, pending regulatory approvals and standard closing conditions.
Two acquisitions in under a year, both closing in the same window, signal a sustained pipeline-building pace. With Ollin, J&J deepens its position in retinal disease, an area where VEGF-targeting drugs have generated some of the industry's largest eye-care franchises.
via qz.com (Source)
More from Olivia Hart
Show full bio
News editor covering regulation, policy and their impact on corporate strategy and chief-executive leadership at CEO Frontier.
497 articles
Adjacent sheets
- Johnson & Johnson Commits More Than $1 Billion to Jacksonville Vision Plant
- Isomorphic Labs raises $5 billion to push AI drug candidates to trials
- Sarepta Names Former AbbVie Executive Michael Severino CEO
- AstraZeneca weighs cancer vaccines as Phase 3 data emerge
- Eli Lilly to Buy Blood Cancer Biotech Calytrix for Up to $1.5 Billion